LDLev V. Demidov

Lev V. Demidov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lev V. Demidov has a total of 391 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The RATIONALE study: Outcomes of targeted therapy for metastatic melanoma in Russia

    by I. V. Samoylenko, K. V. Orlova, N. V. Leushina, A. V. Shkradyuk, O. V. Mironov, I. A. Pokataev, O. O. Shesterikova, O. V. Romachuk, O. A. Snezhko, T. V. Chupriianova, et al.

    Introduction. The efficacy of targeted therapy with the combination of dabrafenib and trametinib in patients with metastatic cutaneous melanoma harboring BRAF mutations has been demonstrated in randomized clinical trials (COMBI-d/v, COMBI-i) and confirmed in real-world clinical practice. The present study aimed to evaluate survival outcomes, tolerability, and treatment modification rates, taking into account the characteristics of clinical practice and the patient population in Russia. The findings are important for optimizing therapeutic strategies and improving the quality of healthcare. Aim. To evaluate the efficacy and safety of dabrafenib plus trametinib in Russian patients with metastatic cutaneous melanoma harboring BRAF V600 mutation in a real-world setting. Materials and methods. RATIONALE is a prospective, non-interventional, multicenter study. A total of 283 patients with unresectable stage IIIC-D and IV melanoma were included. Patients aged ≥ 18 years with metastatic cutaneous melanoma initiated dabrafenib plus trametinib no more than 4 weeks prior to enrolment. The follow-up period was 1 year. Results. Elevated LDH levels were observed in 33.3% of patients, metastases in ≥ 3 organs in 26.5%, and CNS involvement in 18.4%. The 1-year progression-free survival rate was 54% (95% CI: 48–61%), and overall survival was 78% (95% CI: 73–83%). The objective response rate reached 58.0%, with a median time to response of 3.2 months. Adverse events were reported in 35.7% of patients (grade ≥ 3: 12.0%); the most common was pyrexia (16.6%; grade ≥ 3: 4.2%). Treatment discontinuation due to adverse events occurred in 4.6% of patients. Conclusion. In real-world clinical practice, BRAF/MEK targeted therapy has demonstrated effectiveness in the Russian patient population, with outcomes consistent with those observed in randomized clinical trials, despite substantial population heterogeneity and the inclusion of patients with unfavorable prognostic factors.

  • Open Access

    Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in BRAF metastatic melanoma: updated 4-year OS analyses

    by I. V. Samoylenko, Yu. M. Kolontareva, E. V. Kogay, N. V. Zhukova, I. A. Utyashev, M. E. Ivannikov, K. V. Menshikov, M. V. Zinkevich, K. V. Orlova, Yu. V. Vakhabova, et al.

    Introduction . Combined immune-targeted therapy is a new registered approach for treating metastatic melanoma. Identifying subgroups of patients who may benefit more from simultaneous rather than sequential administration of triple combination drugs is of current scientific interest to the medical community. Aim . To present a 4-year updated analysis of the efficacy and safety of triple therapy with atezolizumab + vemurafenib + cobimetinib (AVC) in patients with BRAF-mutated advanced melanoma in real-world clinical practice in Russia. Materials and methods . A prospective non-interventional study included 59 patients with metastatic BRAF+ melanoma receiving the triple combination of vemurafenib, cobimetinib, atezolizumab. The primary endpoint was 24-month OS. Additionally, PFS, ORR, and risk factors influencing OS were evaluated. This paper is a 4-year update of a previously published analysis. Results . The median OS in the entire population was 23.67 months (95% CI 13.19–NR), and the median PFS in the entire population was 14.97 months (95% CI 8.00–24.39). An objective response was recorded in 57.6% of patients. Cox multivariate analysis revealed a significant impact of age, presence of lung metastases, and large tumor mass (10–15 cm vs ≤6 cm) on OS. The presence of liver metastases reduced median survival by more than 2.5 times, but no significant effect was proven. BMI, ECOG ≥ 2, CNS metastases, line of therapy, and PD-L1 did not have a statistically significant effect. Conclusion . Triple therapy demonstrates high clinical efficacy in patients with metastatic BRAF+ melanoma in real-world clinical practice in the analyzed population of patients with an unfavorable prognosis – CNS involvement, liver involvement, and second-line and subsequent therapy. Age, the presence of lung metastases, and tumor size were found to be prognostic factors affecting survival.

  • Open Access

    Adjuvant targeted therapy in patients with skin melanoma: evidence from Russian real-world clinical practice (RATIONALE study)

    by Igor V. Samoylenko, Kristina V. Orlova, Denis A. Tantsyrev, Sergey V. Sharov, Alexander V. Sultanbaev, Arshak A. Akopyan, Nadezhda V. Leushina, Akhmed Y. M.Z. Abdelgafur Omar, Ilya A. Pokataev, Tatiana V. Chupriianova, et al.

    Background. Adjuvant targeted therapy (ATT) with a combination of dabrafenib and trametinib after radical surgical treatment in patients with stage III skin melanoma (SM) with a BRAF V600 mutation reduces the risk of disease recurrence. The effectiveness of this approach has been demonstrated in randomized clinical trials, and also confirmed in several large non-Russian real-world (RW) studies. Aim. To evaluate, in RW settings, the effectiveness of ATT with a combination of dabrafenib and trametinib after definitive surgical treatment in patients with BRAF V600-positive SM in Russia. Materials and methods. The RATIONALE study is a prospective, non-interventional, multicenter RW study. The follow-up duration for the study was 1 year. Patients with SM older than 18 years who had previously started dabrafenib and trametinib therapy no more than 8 weeks prior to Visit 1 were included in the study. The paper presents results from the analysis of Cohort 1 only (patients who received dabrafenib and trametinib in the adjuvant setting). Results. The cohort included 214 patients with BRAF V600-mutated SM of stages IIIA–D and IV resectable. At the time of therapy initiation, the majority of patients were stage IIIc (54.7%) or IIIb (22.0%). The most common mutation – BRAF V600E – occurred in 66.3% of cases, while the second most common variant – BRAF V600 not otherwise specified – was detected in 31.3%. One-year overall survival for all included patients was 94%, one-year relapse-free survival was 84%, and one-year distant metastasis-free survival was 86%. No previously listed adverse events were reported. Adverse events led to therapy discontinuation in only 11.7% of cases. ATT did not reduce patients' quality of life. In the subgroup analysis, the effectiveness of the combination of dabrafenib and trametinib after removal of distant metastases (equivalent to stage IV resectable) was found, in particular, the one-year relapse-free survival rate was 83%, and the one-year overall survival rate was 100%, which is comparable to these indicators for stage IIIB-D (72–86 and 78–100%, respectively). Conclusion. The effectiveness and favorable safety profile of the combination of dabrafenib and trametinib in ATT after radical surgical treatment was confirmed in a population of Russian patients with SM in the RW settings.


  • Open Access

    Common forms of basal cell carcinoma of the skin: The first experience with sonidegib in the B-SURE observational study in Russia

    by Kristina V. Orlova, Valeria V. Nazarova, Natalia N. Petenko, Lev V. Demidov

    Background. Locally advanced (laBCC) and metastatic basal cell carcinoma of the skin (mBCC) have a poor prognosis. Hedgehog (Hh) pathway inhibitors, such as vismodegib and sonidegib, are highly effective in treatment of advanced forms of BCC. Aim. To evaluate the efficacy and safety of sonidegib in the investigator-initiated observational study B-SURE (Basal cell carcinoma – Sonidegib Use in Real-world Evidence) in patients with laBCC and mBCC in real-world clinical practice in the Russian Federation as first-line therapy (in patients with no history of treatment with Hh inhibitors), as well as in patients with a history of treatment with vismodegib (another Hh pathway inhibitor). Materials and methods. The study included 10 patients, 9 with laBCC and 1 with mBCC. Patients visited clinical center in accordance with routine clinical practice and underwent standard procedures and examinations in accordance with clinical guidelines and the physician’s decision. Visit intervals were 3–4 months. Data on patients’ use of sonidegib was collected during visits to the clinical site, and the efficacy of sonidegib therapy was assessed according to RECIST 1.1 criteria. The patients also completed the EORTC QLQ-C30, version 3, and the EQ-5D-5L, version 1.2, before starting sonidegib therapy and every 3 months thereafter during routine visits to clinic. Results. At the time of data analysis (September 2025), the efficacy of sonidegib therapy was evaluated in 9 patients, while tolerability and safety were evaluated in all 10 patients. Three patients had a history of vismodegib therapy, which was discontinued due to disease progression (n=1), intolerance (n=1), and intolerance with a complete clinical response (n=1). The median time from diagnosis to the development of laBCC and mBCC was 67.5 months. In patients with no prior vismodegib treatment, objective responses were observed in 4 of 7 patients (2 complete, 2 partial responses), yielding an objective response rate (ORR) of 57%. In patients with a history of vismodegib treatment, an objective response was reported in 1 of 3 (complete response in 1), yielding an ORR of 33.3%. The safety profile of sonidegib included adverse events (AEs) in 7 (70%) of 10 patients, mainly of Grade 1-2, which did not require a change in the dose regimen. Severe AEs (Grade 3-4) leading to discontinuation were reported in 1 patient (10%). It is noteworthy that in three patients with severe AEs during previous vismodegib therapy, sonidegib treatment was not associated with such complications, suggesting different safety profiles of these agents. Conclusion. For the first time, the efficacy of sonidegib, with an ORR of 57%, was demonstrated in a Russian population of Hh inhibitor-naive patients with laBCC and mBCC. Sonidegib demonstrated an acceptable safety profile, with a low discontinuation rate (10%) due to AEs. Particular attention should be given to the favorable tolerability of sonidegib in patients with a history of severe toxicity during vismodegib therapy, which expands the therapeutic options in case of intolerance to another Hh-inhibitor.

  • Open Access

    The State of Oncology Care for Melanoma Skin Cancer (C43) in Russia: One- and Five-Year Patient Survival. Localization and Histological structure (A Population-Based Study)

    by Вахтанг Михайлович Мерабишвили, Лев Вадимович Демидов, Игорь Вячеславович Самойленко, Алексей Михайлович Беляев, Alexey M. Belyaev

    Введение. Показатель выживаемости больных злокачественными новообразованиями (ЗНО) наиболее точно характеризует весь комплекс проводимых противораковых мероприятий. При территориальных сравнениях чаще всего используется показатель наблюдаемой и относительной выживаемости, который является отношением рассчитанного показателя наблюдаемой выживаемости к гипотетическому показателю ожидаемой выживаемости. Это международный стандарт оценки эффективности борьбы с раковыми заболеваниями. Цель. Продолжить изучение особенностей динамики основных параметров оценки деятельности онкологической службы относительно больных злокачественной меланомой кожи (ЗМК). Уделить основное внимание характеру динамических процессов наблюдаемой и относительной однолетней и кумулятивной пятилетней выживаемости больных ЗМК с учетом детальной локализационной и гистологической структуры опухолей, стадии заболевания и возрастно-половых особенностей. Материалы и методы. Материалом исследования являются справочники МНИОИ им. П.А. Герцена, НМИЦ онкологии им. Н.Н. Петрова и база данных (БД) популяционного ракового регистра Северо-Западного федерального округа России (СЗФО РФ) объемом 1,7 млн наблюдений, в том числе 24 028 больных ЗМК за период с 2000–2004 по 2020–2022 гг. с учетом пола, возраста и гистологической структуры. Результаты. Проведенное исследование подтвердило продолжающийся рост заболеваемости ЗМК в мире и России, снижение смертности. Однолетняя наблюдаемая выживаемость больных в СЗФО РФ возросла с 2000–2004 по 2020–2022 гг. с 80,6 до 87,0 %, пятилетняя — с 51,9 до 56 % к 2015–2019 гг. Относительная однолетняя выживаемость была на 1–3 % выше, пятилетняя — на 2–9 %. Наибольшую долю поверхности тела среди мужского и женского населения заняла ЗМК туловища, соответственно, 53,5 и 35,3 % с уровнем однолетней выживаемости 85,2 и 89,2 %. Отмечен рост практически всех повозрастных показателей выживаемости, составляющих среди мужского населения более чем 80 % для больных в возрасте 70 лет возраста и среди женского населения более 90 % до 65-летнего возраста. Среди населения старческого возраста и долгожителей — достижения скромнее. Однолетняя выживаемость учтенных больных с первой стадией заболевания превысила 97 %, с четвертой — снизилась с 26,7 до 35,8 %

  • Open Access

    Immunotherapy Combined with Stereotactic Radiotherapy or Isolated Hepatic Perfusion for Metastatic Uveal Melanoma: Preliminary Study Results

    by Захра Рамазановна Магомедова, Валерия Витальевна Назарова, Кристина Вячеславовна Орлова, Екатерина Андреевна Азарова, Владимир Михайлович Унгурян, Денис Сергеевич Романов, Роман Владимирович Москаленко, Рафаэль Ринатович Файзуллин, Оксана Петровна Трофимова, Лев Вадимович Демидов, et al.

    Введение. Метастатическая увеальная меланома (мУМ) характеризуется неблагоприятным прогнозом и ограниченным числом возможных опций терапии. Одним из основных вариантов лечения лекарственными средствами на сегодняшний день остаются ингибиторы контрольных точек иммунитета (ИКТИ), несмотря на их низкую эффективность. Комбинированные подходы с локальными методами лечения, такими как стереотаксическая лучевая терапия (СТЛТ) или изолированная перфузия печени (ИПП) мелфаланом, потенциально могут продемонстрировать синергизм между собой и тем самым повысить показатели эффективности. Цель. Оценить эффективность и безопасность терапии ингибиторами контрольных точек (анти-PD-1 или анти-PD-1+анти-CTLA-4) в сочетании с СТЛТ или ИПП у пациентов с мУМ. Материалы и методы. Данная работа является продолжающимся несравнительным когортным исследованием. Включались пациенты с ECOG-статусом 0–1 с метастатической увеальной меланомой старше 18 лет, ранее не получавшие системную терапию, имеющие как минимум один измеряемый очаг по критериям RECIST 1.1. Все они получали иммунотерапию (МКА анти-PD-1 монотерапия или комбинация МКА анти-PD-1+анти-CTLA-4) в сочетании с СТЛТ при наличии ≤ 3 метастатических очагов на один орган или ИПП мелфаланом при поражении печени < 50 %; допустимо наличие стабильных метастатических очагов в других органах. Результаты. С сентября 2019 по апрель 2025 г. включено 43 пациента, получавших сочетании ИКТИ и локальных методов (21 — в группу СТЛТ, 22 — в группу ИПП). В группе СТЛТ частота объективного ответа составила 42,8 %, шестимесячная ВБП (выживаемость без прогрессирования) — 66,7 % (95 % ДИ 42,5–82,5); медиана ВБП — 8,6 мес. (95 % ДИ 4,4–13,8), медиана общей выживаемости (ОВ) — 44,7 мес. (95 % ДИ 16,9–НД (не достигнута). В группе ИПП частота объективного ответа составила 45 %, шестимесячная ВБП — 72 % (95 % ДИ 48–86), медиана ВБП — 10,1 мес. (95 % ДИ 5,0–15,5), медиана ОВ не достигнута. Нежелательные явления (НЯ) 3–5-й степени наблюдались у 14,3 (СТЛТ) и 45,5 % (ИПП) пациентов. Выводы. Комбинация ингибиторов контрольных точек иммунитета с СТЛТ или ИПП демонстрирует высокую эффективность и удовлетворительную переносимость при метастатической увеальной меланоме для пациентов с различным объемом метастатического поражения и требует дальнейшего изучения.

  • Open Access

    Expert Consensus Statement: Sonidegib for the Treatment of Locally Advanced Basal Cell Carcinoma

    by Кристина Вячеславовна Орлова, Игорь Вячеславович Самойленко, Наталия Николаевна Петенко, Валерия Витальевна Назарова, Али Мурадович Мудунов, Татьяна Юрьевна Семиглазова, Замира Ахмедовна Раджабова, Григорий Владимирович Зиновьев, Александр Александрович Феденко, Андрей Павлович Поляков, et al.

    15 мая 2025 г. состоялся экспертный совет «Возможности терапии местнораспространенного базальноклеточного рака препаратом “Сонидегиб”», по итогам которого эксперты подготовили резолюцию. В ней обозначены основные положения, касающиеся современных подходов к системной терапии местнораспространенных форм базальноклеточного рака кожи.

  • Open Access

    Changes in clinical guidelines of 2023 and 2025 on treatment of cutaneous and mucosal melanoma

    by I. V. Samoylenko, Ya. V. Belenkaya, M. E. Abramov, M. D. Aliev, S. M. Banov, T. S. Belysheva, G. I. Gafton, A. V. Golanov, L. V. Demidov, N. V. Zhukova, et al.

    The article presents a comparative analysis of Russian clinical recommendations on treatment of melanoma of the skin and mucous membranes during a period of 2020 and 2023, as well as foreign recommendations of N CCN (National Comprehensive Cancer Network) and ESMO (European Society for Medical Oncology) of 2025. The main debatable issues related to changes on melanoma therapy in 2025 are presented for discussion. The topic of modifying the treatment of patients with melanoma with metastases in the brain is highlighted. New treatment options for patients with metastatic and unresectable (stage IIIC–D) melanoma are discussed, as well as the neoadjuvant and adjuvant therapy options for stage II–III cutaneous melanoma. Various treatment options for patients with local stage melanoma are considered. Among other, the recommendations of 2025 are supplemented with treatment options for melanoma in children.Aim. To highlight changes in clinical guidelines for treatment of melanoma of the skin and mucous membranes for use in daily clinical practice.


  • Open Access

    Rechallenge with BRAF and MEK inhibitors in the treatment of metastatic melanoma: A case report with a mini-review

    by I. V. Samoylenko, A. R. Zaretsky, E. V. Prozorenko, L. V. Demidov

    The management of patients with metastatic melanoma remains a difficult clinical problem. Real-world practice of treating patients with encorafenib and binimetinib after progression on combination immunotherapy and combination targeted therapy demonstrates good tolerability and achievements in disease control, including the central nervous system. After progression on chemotherapy, combination targeted therapy, and combination immunotherapy, the patient developed extensive brain and spinal cord lesions and suffered from neurological symptoms (headache, neck pain, back pain, seizures). Rechallenge with BRAFi+MEKi inhibitors and switching to new generation drugs allowed us to achieve disease control, regression of neurological symptoms and a good quality of life for more than 12 months. This clinical case demonstrates the potential efficacy of rechallenge with combination targeted therapy and switching to newer class drugs, which helps achieve a long-term disease control and improve the patient’s quality of life. The article also provides a discussion of possible management strategies for patients who have progressed on currently available BRAFi + MEKi inhibitors.

  • Open Access

    The Use of Transarterial Chemoembolization in the Treatment of Patients with Uveal Melanoma with Isolated Metastatic Liver Disease.

    by D. V. Martynkov, V. Y. Kosirev, V. V. Nazarova, L. V. Demidov, I. V. Pogrebnyakov, E. R. Virshke, D. Yu. Frantsev, Yu. V. Buydenok, Boris I. Dolgushin, Д. Ю. Францев

    Purpose: To evaluate the tolerability and efficacy of transarterial chemoembolization (TACE) in the treatment of patients with metastatic liver disease from uveal melanoma. Materials and methods: From 2000 to 2024, 131 patients with uveal melanoma underwent liver TACE for metastatic liver disease at the N.N. Blokhin National Medical Research Center of Oncology of the Russian Ministry of Health. The treatment was carried out for multiple bilobar liver disease (110 patients) and solitary/single liver metastases (21 patients). A total of 283 TACEs were performed. The duration of observation after TACE ranged from 1 to 152 months. The median observation was 11 months. Results: TACE was technically successful in 100 % of cases. Postembolization syndrome of varying severity was observed in 82.4 %. Mortality 0 %. Local response (according to mRECIST) was observed in 75/131 (57.2 %) patients. Overall survival (OS) (n=131) was: 1-year — 78.5 %, 2-year — 47 %, %, 3-year — 17 %. Median overall survival was 23 months. In the group of patients who received only TACE (n=29): 1-year OS — 66 %, 2-year OS — 27 %, 3-year OS — 13 %. In the TACE + additional treatment group (n=102) — 1-year OS — 82.2 %, 2-year OS — 50.3 %, 3-year OS — 23.7 %. Conclusions: TACE is a safe treatment option for patients with uveal melanoma with different volumes of liver metastases. Local response in slightly more than half of patients indicates the need for a more rigorous definition of indications for this intervention. Ourresults with TACE indicate the need for further research to determine the optimal timing of the combination of regional interventional treatment with systemic drug therapy, surgery, and liver chemoperfusion.